Loading organizations...
Key people at Cenexum Technologies.
Cenexum Technologies was founded in 2022 by Lasse Richter Petersen (Co-founder & Chief Business Officer).
Cenexum Technologies is a biotechnology company focused on developing therapeutics and diagnostics solutions, operating from an undisclosed headquarters location within the life sciences sector. The firm functions as a portfolio company that builds and commercializes biotech ventures by leveraging cross-disciplinary expertise in pharmaceuticals, biotechnology, and finance. Cenexum collaborates on advanced genomics and epilepsy research projects with prominent institutions and partners, including Aarhus University, Aarhus University Hospital, Epilepsy Hospital Filadelfia, and Qmed Consulting. The organization is backed by venture capital firm Ventac Partners, participating in their specialized 'Build a Biotech' program at NTNU, and recently secured an Innofounder Grant from Innovation Fund Denmark to support its ongoing research and development initiatives. While the exact founding year remains unlisted, the company is led by a 3-person management team that includes Mikael Oerum, Dennis B. Henriksen, and Poul Sørensen.
Key people at Cenexum Technologies.
Cenexum Technologies was founded in 2022 by Lasse Richter Petersen (Co-founder & Chief Business Officer).
Cenexum Technologies is a Denmark-based biotech startup founded in 2022 that develops wireless neural interfacing technology for bi-directional communication with nerve tissue. This powers next-generation neuromodulation devices, including miniaturized, wirelessly powered implants that enable closed-loop, bio-inspired data processing and stimulation for treating neurological and psychiatric disorders like chronic pain, depression, Parkinson's, Alzheimer's, epilepsy, and movement disorders.[1][3][6] With 8 employees, the company targets patients, neurosurgeons, and medical professionals, offering safer alternatives to traditional neurostimulation by eliminating implanted batteries, reducing surgical risks, and incorporating AI/ML for personalized adjustments.[1][2]
The technology features wireless communication via mild electrical impulses, potential for networking multiple implants across the nervous system, and implantation at disease core sites, addressing limitations of wired or battery-dependent devices used as last-resort therapies over the past two decades.[1][4]
Cenexum emerged as a spin-out from Aarhus University, pioneering minimally invasive neurostimulation from academic research into a commercial venture.[3] Founded in 2022 and headquartered in Gentofte, Denmark, the company builds on two decades of established electrical neurostimulation therapies.[1][4][5]
Key figures include Chairman Mikael Oerum, with 40 years in pharma, biotech, and finance, including 25 years as CEO, raising over $300M, negotiating multimillion-dollar deals, and leading IPOs and acquisitions at firms like Exiqon (acquired by Qiagen) and Santaris Pharma (sold to Roche).[2] Dennis Henriksen, linked as founder and former CEO of Sanos Bioscience, provides expertise in biotech services like business plans, regulatory strategy, clinical development, IP, and fundraising; his firm CENSE offers lab facilities for neurohistological analysis of neuromodulation devices.[2] Early traction stems from university technology transfer, humanizing the team's shift from research to addressing unmet needs in nerve interfacing.[3]
Cenexum rides the neuromodulation wave, where electrical stimulation has become a standard last-resort therapy, now evolving with wireless, AI-driven implants amid rising demand for personalized treatments for neurological/psychiatric disorders affecting millions globally.[1][4] Timing aligns with advances in bio-inspired computing, miniaturization, and ML, enabling closed-loop systems that adapt in real-time—critical as aging populations drive Parkinson's, Alzheimer's, and epilepsy prevalence.[1][3]
Market forces favor it: regulatory progress in neuromodulation (e.g., FDA approvals for similar devices), university spin-out momentum in Europe, and investor interest in biotech hardware reducing invasiveness. Cenexum influences the ecosystem by pushing wireless standards, potentially accelerating adoption in neurosurgery and integrating with brain-computer interfaces, bridging academia to clinical impact.[2][3]
Cenexum is poised for clinical trials and partnerships, leveraging its spin-out roots and expert team to secure funding—echoing Oerum's $300M+ raises—and validate implants in human studies for high-need indications like chronic pain or epilepsy.[1][2] Trends like AI-personalized medicine, wireless medtech scalability, and neurotech convergence (e.g., with BCIs) will propel growth, especially as battery-free designs lower barriers to widespread use. Influence may expand via licensing or acquisitions by big pharma, solidifying Denmark's biotech hub status and transforming neuromodulation from last-resort to frontline therapy—building directly on its wireless nerve communication breakthrough.[1][3][6]
